Radiological Biological Genetic and Micro-architectural Bone Determinants of Fractures in Men With Low Bone Mineral Density

Exclusion Criteria

• •Patient or control subject with no affiliation at health national system (beneficiary or co-beneficiary)
• •Subject who received any corticoid treatment more than 3 months along
• •Subject with any known seropositivity for HIV
• •Subject with a chronic inflammation disease (rheumatoid polyarthritis, ankylosing spondylarthritis, inflammatory bowel)
• •Subject with secondary osteoporosis documented by clinical and biological examinations (serum calcium, serum phosphate, serum phosphatase alkaline, gamma GT, testosterone) in order to eliminate any chronic alcoholism, alcoholic cirrhosis, hypogonadism, osteomalacia, hemochromatosis, hyperthyroidism, primitive hyperparathyroidism, hypercorticism
• •Subject who received treatment with bisphosphonates intravenously
• •Subject who received a treatment with bisphosphonates (Actonel® or Fosamax®) for at least 5 years and stopped since less than 2 years
• •Subject who received a treatment with bisphosphonates for at least 3 years and stopped since less than 1 year
• •Subject who received a treatment with bisphosphonates during the 6 months before inclusion